XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 583.52%622M | 109.60%415M | 107.25%143M | 2,307.69%287M | -36.81%-223M | -88.93%91M | 67.80%198M | -48.51%69M | -102.43%-13M | -579.41%-163M |
Net income from continuing operations | 103.10%24M | 188.99%202M | 150.78%98M | 125.62%31M | -32.33%-307M | -2,134.21%-773M | 45.95%-227M | 74.90%-193M | -117.95%-121M | -141.95%-232M |
Operating gains losses | -85.26%37M | -118.92%-7M | -25.76%49M | -181.48%-44M | -58.51%39M | 945.83%251M | -61.86%37M | -15.38%66M | 143.20%54M | 461.54%94M |
Depreciation and amortization | 1.58%642M | -2.45%159M | -2.45%159M | 6.54%163M | 5.23%161M | 2.43%632M | 10.88%163M | 9.40%163M | -4.97%153M | -4.38%153M |
Deferred tax | 204.55%23M | -76.87%31M | 155.83%67M | 0.00%-12M | -162.50%-63M | -110.05%-22M | 6.35%134M | ---120M | -112.37%-12M | -500.00%-24M |
Other non cash items | 50.84%359M | 2,350.00%90M | 47.37%28M | -16.67%25M | 11.92%216M | -67.49%238M | -133.33%-4M | -97.08%19M | 133.33%30M | 21.38%193M |
Change In working capital | -84.81%-499M | -174.71%-65M | -308.59%-267M | 187.50%112M | 21.85%-279M | 68.16%-270M | -39.58%87M | 652.94%128M | 33.33%-128M | 56.30%-357M |
-Change in receivables | -574.04%-493M | -7,175.00%-291M | 118.92%81M | -329.03%-71M | -630.00%-212M | 276.27%104M | 95.12%-4M | -78.98%37M | 193.94%31M | 133.33%40M |
-Change in inventory | -79.01%51M | -136.36%-28M | -154.17%-78M | 1,620.00%86M | 317.65%71M | 144.42%243M | 133.33%77M | 87.01%144M | 102.81%5M | 103.55%17M |
-Change in prepaid assets | -274.36%-68M | -300.00%-56M | -250.00%-35M | -50.85%29M | -250.00%-6M | -11.36%39M | -125.93%-14M | 60.00%-10M | 96.67%59M | 126.67%4M |
-Change in payables and accrued expense | 150.14%177M | 286.02%359M | -760.00%-165M | 160.71%85M | 69.18%-102M | -159.56%-353M | -6.06%93M | 116.56%25M | -226.13%-140M | -69.74%-331M |
-Change in other current assets | 98.10%-4M | --0 | 74.34%-29M | 143.24%16M | 131.03%9M | -141.38%-210M | -542.86%-31M | -391.30%-113M | 63.00%-37M | -200.00%-29M |
-Change in other current liabilities | -74.19%-162M | -44.12%-49M | -191.11%-41M | 28.26%-33M | 32.76%-39M | -47.62%-93M | -203.03%-34M | 221.62%45M | -109.09%-46M | -56.76%-58M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 583.52%622M | 109.60%415M | 107.25%143M | 2,307.69%287M | -36.81%-223M | -88.93%91M | 67.80%198M | -48.51%69M | -102.43%-13M | -579.41%-163M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -3.93%-608M | 11.68%-174M | 7.83%-153M | -36.67%-164M | -14.71%-117M | -18.18%-585M | -15.20%-197M | -20.29%-166M | -29.03%-120M | -9.68%-102M |
Capital expenditure reported | -9.23%-580M | 10.11%-169M | -0.69%-146M | -42.61%-164M | -21.69%-101M | -10.63%-531M | -9.94%-188M | -13.28%-145M | -7.48%-115M | -12.16%-83M |
Net investment purchase and sale | 47.14%-37M | 63.16%-7M | 13.33%-13M | --0 | 15.00%-17M | -218.18%-70M | ---19M | -36.36%-15M | -260.00%-16M | 4.76%-20M |
Net other investing changes | -43.75%9M | -80.00%2M | 200.00%6M | --0 | 0.00%1M | 128.57%16M | --10M | -700.00%-6M | 175.00%11M | -50.00%1M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -3.93%-608M | 11.68%-174M | 7.83%-153M | -36.67%-164M | -14.71%-117M | -18.18%-585M | -15.20%-197M | -20.29%-166M | -29.03%-120M | -9.68%-102M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 252.63%201M | -6,666.67%-394M | -340.00%-84M | -212.50%-75M | 1,785.00%754M | 107.42%57M | 124.00%6M | 118.92%35M | 93.12%-24M | 119.14%40M |
Net issuance payments of debt | 541.82%353M | -2,607.14%-351M | -159.38%-19M | -40.00%-21M | 3,000.00%744M | 1,733.33%55M | 366.67%14M | --32M | ---15M | --24M |
Net common stock issuance | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash dividends paid | -25.00%-90M | -50.00%-27M | -44.44%-26M | 0.00%-18M | -5.56%-19M | 0.00%-72M | -5.88%-18M | 0.00%-18M | 5.26%-18M | 0.00%-18M |
Proceeds from stock option exercised by employees | --0 | --0 | --0 | --0 | --0 | -95.45%1M | --0 | --0 | --0 | -95.24%1M |
Net other financing activities | -184.93%-62M | -260.00%-16M | -285.71%-39M | -500.00%-36M | -12.12%29M | 133.03%73M | 190.91%10M | 223.53%21M | 116.07%9M | 124.09%33M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 252.63%201M | -6,666.67%-394M | -340.00%-84M | -212.50%-75M | 1,785.00%754M | 107.42%57M | 124.00%6M | 118.92%35M | 93.12%-24M | 119.14%40M |
Net cash flow | ||||||||||
Beginning cash position | -28.97%1.05B | 36.89%1.41B | 36.10%1.49B | 16.31%1.46B | -28.97%1.05B | -23.39%1.47B | -33.16%1.03B | -37.24%1.1B | -24.86%1.25B | -23.39%1.47B |
Current changes in cash | 149.20%215M | -2,285.71%-153M | -51.61%-94M | 130.57%48M | 284.00%414M | 0.91%-437M | 108.97%7M | 67.20%-62M | -267.02%-157M | 16.04%-225M |
Effect of exchange rate changes | -380.00%-28M | -330.00%-23M | 320.00%11M | -433.33%-10M | -400.00%-6M | 211.11%10M | -9.09%10M | 72.22%-5M | 127.27%3M | -77.78%2M |
End cash Position | 17.86%1.23B | 17.86%1.23B | 36.89%1.41B | 36.10%1.49B | 16.31%1.46B | -28.97%1.05B | -28.97%1.05B | -33.16%1.03B | -37.24%1.1B | -24.86%1.25B |
Free cash flow | 109.55%42M | 2,360.00%246M | 96.05%-3M | 196.09%123M | -31.71%-324M | -228.65%-440M | 118.87%10M | -1,366.67%-76M | -129.84%-128M | -515.00%-246M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |